NASDAQ · HYPD
Healthcare · Medical - Devices
$3.18
Up+$0.04 (+1.27%)
Updated Aug 22, 2026, 4:06 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
HYPD closed at $3.18 after 21 trading sessions, up 26.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $3.27 | $3.57 | $3.13 | $3.18 | 833.43K |
| Aug 20, 2026 | $3.21 | $3.2199 | $2.86 | $3.14 | 1.02M |
| Aug 19, 2026 | $2.74 | $3.32 | $2.67 | $3.04 | 2.17M |
| Aug 18, 2026 | $2.83 | $2.92 | $2.70 | $2.70 | 205.31K |
| Aug 17, 2026 | $2.75 | $2.91 | $2.74 | $2.84 | 198.78K |
| Aug 14, 2026 | $2.85 | $2.86 | $2.71 | $2.72 | 157.61K |
| Aug 13, 2026 | $2.78 | $3.025 | $2.74 | $2.83 | 393.76K |
| Aug 12, 2026 | $2.64 | $2.75 | $2.63 | $2.69 | 123.11K |
| Aug 11, 2026 | $2.61 | $2.66 | $2.56 | $2.64 | 121.94K |
| Aug 10, 2026 | $2.69 | $2.69 | $2.60 | $2.61 | 84.65K |
| Aug 7, 2026 | $2.65 | $2.75 | $2.65 | $2.70 | 114.41K |
| Aug 6, 2026 | $2.65 | $2.73 | $2.60 | $2.67 | 108.44K |
| Aug 5, 2026 | $2.73 | $2.82 | $2.68 | $2.73 | 216.58K |
| Aug 4, 2026 | $2.70 | $2.79 | $2.69 | $2.73 | 171.65K |
| Aug 3, 2026 | $2.63 | $2.73 | $2.53 | $2.66 | 369.7K |
| Jul 31, 2026 | $2.61 | $2.71 | $2.59 | $2.64 | 358.46K |
| Jul 30, 2026 | $2.38 | $2.67 | $2.38 | $2.66 | 211.62K |
| Jul 29, 2026 | $2.39 | $2.47 | $2.34 | $2.34 | 361.74K |
| Jul 28, 2026 | $2.52 | $2.555 | $2.34 | $2.42 | 240.33K |
| Jul 27, 2026 | $2.56 | $2.66 | $2.53 | $2.56 | 111.46K |
| Jul 24, 2026 | $2.64 | $2.64 | $2.51 | $2.51 | 268.32K |
The latest Smart Investors Daily articles mentioning HYPD.
HYPD research
Company profile and research snapshot.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or New combinations.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Chardan Capital | Buy | — |
| Aug 13, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 11, 2026 | Chardan Capital | Buy | — |
| Jul 1, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 8, 2026 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 9, 2026
Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that it has engaged with the HyperLend protocol ("HyperLend") to create a permissioned lending pool native to the HyperEVM.Through this
Benzinga · Jan 28, 2026
Hyperliquid (CRYPTO: HYPE) is up 65% this week, taking the limelight from bigger and presumably more established tokens, such as XRP
seekingalpha.com · Nov 14, 2025
Hyperion DeFi, Inc. ( HYPD ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Jason Assad Hyunsu Jung - CEO, Chief Investment Officer & Director David Knox - Chief Financial Officer Presentation Operator Greetings, and welcome to Hyperion DeFi's Q3 '25 Earnings Call. [Operator Instructions] Please note this conference is being recorded.
SeekingAlpha · Nov 14, 2025
Hyperion DeFi, Inc. (HYPD) Q3 2025 Earnings Call November 13, 2025 5:00 PM ESTCompany ParticipantsJason AssadHyunsu Jung - CEO, Chief Investment Officer...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HYPD.
